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OBJECTIVE The purpose of this study was to assess if simvastatin has an anti-inflammatory activity in
patients with hypercholesterolemia.
BACKGROUND Simvastatin, an inhibitor of 3-hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase,
reduced cardiovascular events in patients with myocardial infarction and hypercholesterol-
emia.
METHODS Sixteen patients with polygenic hypercholesterolemia were randomly allocated to diet (n 5 8)
or diet plus 20 mg/day simvastatin (n 5 8) for eight weeks. Before and at the end of treatment
period, lipid profile and monocyte expression of tumor necrosis factor-a (TNF) and
interleukin-1b (IL-1b) were measured.
RESULTS At baseline no difference in lipid profile and monocyte expression of TNF and IL-1b were
observed between the two groups. In patients allocated to diet alone, no change in lipid profile
and monocyte expression of TNF and IL-1b was seen. In patients with diet plus simvastatin,
significant decreases of total cholesterol (227%, p , 0.02), low density lipoprotein-
cholesterol (233%, p , 0.02), and monocyte expression of TNF (249%, p , 0.02) and
IL-1b (235%, p , 0.02) were observed. At the end of treatment period, patients treated with
simvastatin had lower cholesterol and monocyte TNF and IL-1b than did patients assigned
to diet alone.
CONCLUSION This study suggests that simvastatin possesses anti-inflammatory activity via the inhibition of
pro-inflammatory cytokines TNF and IL-1b expressed by monocytes. (J Am Coll Cardiol
2000;36:427–31) © 2000 by the American College of Cardiology
High serum levels of total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-C) have been associated with
atherosclerosis and increased incidence of thrombotic com-
plications, especially in patients with coronary heart disease
(1–3). Interventional studies showed that cholesterol-
lowering therapy reduces the risk of vascular events in
primary and secondary prevention clinical trials (4,5).
Clinical trials with inhibitors of 3-hydroxy-methyl-
glutaryl coenzyme A (HMG-CoA) reductase (statins) rein-
forced the concept that cholesterol is an important risk
factor for cardiovascular complications. In fact, recent stud-
ies demonstrated that, in patients with elevated as well as
average LDL-C levels, statins reduce the risk of cardiovas-
cular events (6–9).
The mechanisms accounting for this effect include the
regression and/or the inhibition of progression of athero-
sclerotic plaque, which, in turn, would prevent thrombotic
events (10). However, changes of atherosclerotic plaques are
usually observed after four years from statin administration
(11), whereas only two years of such therapy are necessary to
reduce cardiovascular events (6–9). Hence, alternative
mechanisms have been considered for explaining the effects
of statins on atherothrombosis. Among these, the anti-
inflammatory activity is particularly attractive because in-
flammation is considered an early step in the formation and
progression of atherosclerotic plaque (12). Experimental
models showed that cholesterol reduction by pravastatin is
associated with diminished amount of inflammatory cells in
the plaque (13); furthermore, hypercholesterolemic patients
treated with HMG-CoA reductase inhibitors have dimin-
ished monocyte adhesiveness to endothelium (14).
Herein we report the first evidence that simvastatin
reduces the monocyte expression of pro-inflammatory cyto-
kines in patients with polygenic hypercholesterolemia.
MATERIALS AND METHODS
Subjects. We selected 16 patients affected by polygenic
hypercholesterolemia (7 males and 9 females; age 52 6 9
[35 to 70] years). Five patients were current smokers and
four had therapeutically controlled hypertension. All sub-
jects gave written informed consent to participate in the
study. Exclusion criteria were diabetes mellitus, history of
alcohol or drug abuse, body mass index .25, peripheral-,
cardio-, and cerebro-vascular atherosclerotic diseases, con-
comitant inflammatory diseases, drugs modifying lipid me-
tabolism, or blood coagulation.
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Design of study. Patients attended our department after an
overnight fast between 8:00 and 9:00 AM. After a rest period
of at least 20 min, two blood samples were withdrawn from
each patient, without stasis, from the antecubital vein using
a 20-G needle and centrifuged at 1500 g for 10 min. Serum
aliquots were immediately used to measure lipid parameters.
Hypercholesterolemic patients were randomly allocated
to receive diet (total fat intake ,30% of total calories,
cholesterol ,300 mg/day, polyunsaturated/saturated fatty
acids ratio 5 1.0) plus simvastatin (20 mg/day (n 5 8; 3
men and 5 women; 49 6 10 years) or diet alone (n 5 8; 4
men and 4 women; 54 6 9 years) for eight weeks. Safety
biochemical parameters (serum aspartate aminotransferase,
serum alanine aminotransferase, and creatine kinase), lipid
profile, and cytokines expressed by monocytes were mea-
sured before and after the treatment period. The measure-
ment of each variable was performed blind.
METHODS
Total cholesterol (TC) (Cholesterol-ES TM reagent, Beck-
man Instruments Inc., Galway, Ireland), triglycerides
(Triglycerides-INT reagent, Beckman), high density li-
poprotein cholesterol (HDL-C) (HDL-C reagent, Beck-
man) were assayed on all samples. The LDL-C was calcu-
lated according to Friedewald’s formula (15).
Isolation and incubation of blood mononuclear cells.
Peripheral blood mononuclear cells were isolated from
heparinized venous blood using aseptic technique. Platelets
were removed by using two-step centrifugation, once at 140
g and twice at 100 g in PBS at room temperature for 10 min.
Peripheral blood mononuclear cells (PBMCs) were isolated
by centrifugation on lymphoprep (Nyegaard, Oslo Norway)
at 1200 g for 20 min at 20°C (16). Monocytes, identified by
May-Gru¨nwald Giemsa staining comprised 16% to 22%
(mean: 19%).
Monocytes (adherent cells) were obtained by incubation
of the PBMCs for 90 min at 37°C in humidified atmo-
sphere of 5% CO2 in air in Petri dishes containing RPMI-
1640, supplemented with 2 mmol/liter glutamine; lympho-
cytes (nonadherent cells) were removed by aspiration with a
Pasteur pipette and washing of the dishes with warm media
(17). The purified monocyte preparation contained 85% to
95% monocytes. After isolation, cells were washed twice in
PBS and incubated at 2 3 105 cells/ml in RPMI-1640 at
37°C 5% CO2 for 6 h. Cultures were performed in the
presence of LPS (Escherichia coli OB11: B4, Sigma, St.
Louis, Missouri) at a final concentration of 0.4 ng/ml. At
the end of the incubation period, the cells and media were
separated by centrifugation (2,000 g for 15 min).
The cells were washed with Tris-NaCl buffer (0.1 mmol/
liter NaCl, 0.1% bovine serum albumin, pH 7.4) and then
lysed in the same buffer by adding 15 mmol/liter n-octyl-
b-D-glycopyranoside at 37°C for 30 min (18). Cells count
and trypan blue exclusion were performed on cell suspen-
sions after washing.
Tumor necrosis factor-alpha and inteleukin-1-beta.
Monocyte tumor necrosis factor-alpha (TNF) was assayed
in duplicate by and enzyme immunoassay (EIA) (Biokine
TNF test kit, T-Cell Diagnostics, Cambridge, Massachu-
setts) (19). The detection limit was calculated to be 10
pg/ml. Intra- and interassay coefficients of variation were
8% and 9%, respectively. Interleukin-1-beta (IL-1b) levels
(Genzyme Diagnostic, Cambridge, Massachusetts) were
measured by enzyme-immunometric assay according to the
manufacturer’s instructions. Intra- and interassay coeffi-
cients of variation were 4% and 11%, respectively. The low
detection limit of the assay was 6 pg/ml. All samples were
tested in duplicate.
Statistical analysis. Previous study showed that sample
size would have to consist of at least six patients in each
group (alpha 5 0.05 and 1-beta 5 0.90) (20,21), assuming
that simvastatin reduced monocyte tissue factor by 40%. We
postulated that a same sample size was necessary to observe
at least 40% reduction in monocyte TNF and IL-1b.
Statistical analysis was performed by chi-square statistic
and by appropriate t-test. The linear regression test was
used to study the different correlation. When necessary, log
transformation was used to normalize the data. The effect of
treatment was analyzed by two-way repeated measures
analysis of variance (ANOVA). Data were presented as
mean 6 SD, median, and 95% confidence limits. Only
two-tailed probabilities were used for testing statistical
significance. A p value ,0.05 was regarded as statistically
significant (22). All calculations were made using personal
computer software (Stat View II, Abacus Concepts, Berke-
ley, California).
RESULTS
At baseline no difference in TC, tryglicerides, HDL-C,
LDL-C, and monocyte expression of TNF and IL-1b was
observed between the groups assigned to diet or diet plus
simvastatin (Table 1). A significant direct correlation be-
tween monocyte expression of TNF and IL-1b was detected
(rho 5 0.84, p , 0.0001). After eight weeks of treatment,
patients allocated to diet alone did not show significant
changes in lipid profile and monocyte expression of TNF
and IL-1b (Table 1). Conversely, in patients treated with
diet plus simvastatin, a significant decrease of TC (227%)
and LDL-C (233%) was observed, whereas tryglicerides
and HDL-C did not significantly change; furthermore, a
Abbreviations and Acronyms
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significant decrease of monocyte expression of TNF and
IL-1b was detected (Table 1).
Figures 1 and 2 report on individual changes of monocyte
expression of TNF and IL-1b in patients allocated to diet
alone or diet plus simvastatin. In patients treated with diet
plus simvastatin, median decrease of monocyte TNF was
49%: the reduction of monocyte TNF was observed in all
but one patient. A similar finding was observed for IL-1b,
whose median value decreased by 35%: also, for this variable
the reduction was observed in all but one patient. Con-
versely, in patients treated with diet alone, both monocyte
TNF and IL-1b remained somewhat stable over the
follow-up period. The data were also analyzed by two-way
repeated measures ANOVA, which demonstrated a signif-
icant decrease of TNF (p , 0.02) and IL-1b (p , 0.002)
after diet plus simvastatin treatment; the two-way interac-
tion between TNF and IL-1b decreases were statistically
significant (Rao R [2.27] 5 6.64; p , 0.004).
DISCUSSION
Inflammation and atherosclerosis. There is a growing
body of evidence suggesting that inflammation has a crucial
role in the onset and progression of atherosclerosis (12).
Figure 1. Tumor necrosis factor-a expressed by monocytes of hypercho-
lesterolemic patients at the baseline and after diet (left panel) or diet plus
sinvastatin (right panel) treatment.
Figure 2. Interleukin-1b expressed by monocytes of hypercholesterolemic
patients at the baseline and after diet (left panel) or diet plus sinvastatin
(right panel) treatment.
Table 1. Laboratory Indexes in Hypercholesterolemic Patients Treated for Eight Weeks With Diet or Diet Plus Simvastatin
Assay











(N 5 8) p Value*
8th Week
(N 5 8) p Value†
Total cholesterol
(mg/dl)
268.6 6 41.8 265.1 6 42.4 289 6 20.8 217.6 6 31.5
264 . 0.05 263 288 0.012 211 0.045
(200–338) (200–341) (265–331) (161–255)
Triglycerides
(mg/dl)
107.7 6 51 125.8 6 41.2 148.2 6 77.9 131.7 6 60.8
113.5 . 0.05 123.5 152.0 . 0.05 134.0 . 0.05
(48–206) (70–206) (60–305) (69–248)
HDL-cholesterol
(mg/dl)
59 6 9.8 57.4 6 4.8 49.1 6 11.9 52.5 6 9.1
57 . 0.05 57 49 . 0.05 54 . 0.05
(47–77) (52–64) (35–70) (38–62)
LDL-cholesterol
(mg/dl)
188 6 41.8 182.6 6 49 210 6 31.5 138.7 6 32.8
186 . 0.05 170 212 0.012 137 . 0.05
(127–261) (121–270) (162–259) (71–179)
TNF (pg/2 3 105
monocytes)
136.3 6 95.1 147.6 6 98.8 174.7 6 106.3 72.4 6 19.8
118.8 . 0.05 108.7 134.7 0.017 71.5 0.027
(45.4–342.8) (38.0–350.2) (61.6–342.5) (42.2–110.6)
IL-1b (pg/2 3 105
monocytes)
74.6 6 14.3 82.1 6 13.9 88.9 6 21.1 58.8 6 9.6
77.4 . 0.05 78.6 89.3 0.017 57.7 0.0023
(47.9–92.6) (65.1–105.8) (60–118.4) (44.6–74.7)
Data are: mean 6 SD and median (range).
*p Value of Wilcoxon signed rank test; †p value of Mann-Whitney test used to compare the percentage change from baseline.
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The LDL-C oxidation by cells resident in the vessel wall
represents the primum movens of a sequence of events
leading to monocyte adhesion to endothelial cell with
ensuing infiltration in the intima (23,24). Resident macro-
phages, in turn, would contribute to atherosclerotic progres-
sion by virtue of secretion of pro-inflammatory cytokines
that may induce important changes in endothelial function
and favor activation of clotting system. Accordingly, mac-
rophages are present in the site of plaque rupture and seem
to be responsible for acute coronary syndrome by activating
clotting system through over-expression of tissue factor
(25,26). The mechanism by which macrophages contribute
to plaque rupture is still unknown; however, release of
pro-inflammatory cytokines may induce plaque instability
and in turn favor its rupture. Hence, knowledge of the
mechanisms leading to pro-inflammatory cytokines release
by macrophages may be potentially relevant to modulate
plaque instability.
Recent studies suggested that cholesterol biosynthesis is
associated with pro-inflammatory cytokine formation via
mevalonate metabolites. In particular, protein farnesylation
has been shown to induce posttranslation modification of
G-proteins, including RAS, and to elicit activation of MAP
kinase (27,28). Interestingly, incubation of macrophages
with sodium phenylacetate, an inhibitor of mevalonate
phyrophospahte decarboxylase, inhibited formation of pro-
inflammatory cytokines such as TNF and IL-1b (29). A
similar effect was observed by incubating macrophages with
lovastatin, an inhibitor of HMG-CoA reductase; thus,
lovastatin inhibited the monocyte expression of TNF and
IL-1b, thus corroborating the importance of mevalonate
pathway in the intracellular formation of pro-inflammatory
cytokines (29). As this effect has never been demonstrated
after supplementation with an inhibitor of HMG-CoA
reductase we undertook this study to assess if inhibition of
mevalonate pathway is associated with reduced inflamma-
tory cytokines.
Simvastatin treatment and cytokines. We observed that,
after eight weeks of supplementation with simvastatin,
patients with polygenic hypercholesterolemia showed lower
monocyte expression of TNF and IL-1b in comparison to
baseline values, while no significant changes were observed
in patients assigned to diet alone. The effect of simvastatin
on monocyte activity was also reinforced by the fact that at
the end of the treatment period, patients assigned to
simvastatin had lower monocyte expression of TNF and
IL-1b than did patients assigned to diet alone. Reduction of
pro-inflammatory cytokines expression might have potential
clinical implication because of the important role played by
these cytokines in the inflammation of atherosclerotic
plaque (12). In particular, the decreased expression of TNF
may be relevant as TNF promotes formation of oxygen free
radicals, thus contributing to the oxidative stress occurring
within the vessel wall (30). Also, TNF represents an
important link between inflammation and thrombosis inas-
much as it elicits macrophage expression of tissue factor, a
protein of extrinsic clotting pathway that converts factor X
to Xa (31). The decreased expression of TNF by macro-
phages after simvastatin treatment may contribute to explain
our previous data (20) showing that simvastatin reduces in
vivo thrombin generation by inhibiting the monocyte ex-
pression of tissue factor.
Conclusions. This study shows that simvastatin has anti-
inflammatory property by inhibiting the monocyte expres-
sion of TNF and IL-1b. An intriguing corollary of this
study is that cholesterol biosynthesis is a potential flogogen
pathway that contributes to the formation of pro-
inflammatory cytokines. Inhibition of cholesterol biosyn-
thesis is therefore important not only for reducing intracel-
lular cholesterol accumulation but also for inhibiting the
formation of cytokines, which play an important role in
favoring the atherosclerotic plaque instability and poten-
tially contribute to oxidize LDL-C. Hence, we hypothesize
that the reduction of inflammatory components of athero-
sclerotic plaque with eventual plaque stabilization may
represent another mechanism accounting for the reduction
of cardiovascular events observed after simvastatin treat-
ment.
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